Prescrire International最新文献_第10页

prucalopride (Resolor°) and chronic constipation in men: Avoid in both men and women. 普芦卡必利(Resolor°)与男性慢性便秘:男性和女性均避免。

Prescrire International Pub Date : 2016-10-01

引用次数: 0

Quinine, cramps and heart failure: deaths. Quinine has an unfavourable harm-benefit balance in the treatment of cramps. 奎宁，痉挛和心力衰竭:死亡。奎宁在治疗抽筋方面有不利的利弊平衡。

Prescrire International Pub Date : 2016-10-01

引用次数: 0

ruxolitinib (JAKAVI°) and polycythaemia vera Inconclusive evaluation. ruxolitinib (JAKAVI°)和真性红细胞增多症尚无定论。

Prescrire International Pub Date : 2016-10-01

{"title":"ruxolitinib (JAKAVI°) and polycythaemia vera Inconclusive evaluation.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"Patients with polycythaemia vera, a myeloproliferative syndrome, are at increased risk of thrombotic events. Marrow fibrosis and transformation to acute leukaemia can also occur after several years. Treatment is based on phlebotomy and aspirin at low (antiplatelet) doses, sometimes combined with hydroxycarbamide, a cytotoxic drug. Various other drugs are available if hydroxycarbamide fails or is poorly tolerated, but there is no consensus treatment. Ruxolitinib inhibits Janus tyrosine kinases, which are involved, among other roles, in haematopoiesis. Ruxolitinib has been authorised in the European Union for patients with polycythaemia vera in whom hydroxycarbamide has failed or is poorly tolerated. Clinical evaluation of ruxolitinib in this setting is based on a randomised, unblinded trial versus treatment chosen by the investigators, in 222 patients treated for 32 weeks. Hydroxycarbamide was chosen in 59% of cases, even though the patients had unacceptable adverse effects or an inadequate response to the drug. The efficacy of the investigators' other treatment choices was uncertain. Phlebotomy was less frequent in the ruxofitinib group than in the control group. The adverse effects of ruxotitinib in this situation are poorly documented, due to inadequate long-term assessment. In the short term, ruxolitinib causes anaemia and thrombocytopenia, as well as bleeding, potentially severe infections, headache, sensory disturbances, and weight gain. It is also likely to share the serious adverse effects of other immunosuppressants. Ruxolitinib is mainly metabolised by cytochrome P450 isoenzymes CYP3A4 and CYP2C9, creating a risk of multiple drug interactions. Ruxolitinib showed embryofetal toxicity in animal studies. Virtually no data are available in pregnant women. In practice, available data on the harm-benefit balance of ruxolitinib fail to show that this drug represents a tangible advance for patients with polycythaemia vera, as compared with other drugs used when hydroxycarbamide is unsuitable.","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"25 175","pages":"229-231"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36855051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation. Providing balanced information to male patients is key. 非那雄胺1毫克治疗脱发:性功能障碍、自杀意念。向男性患者提供平衡的信息是关键。

Prescrire International Pub Date : 2016-10-01

引用次数: 0

MedDRA and pharmacovigilance: a complex and little-evaluated tool. MedDRA和药物警戒:一个复杂的和很少评估的工具。

Prescrire International Pub Date : 2016-10-01

{"title":"MedDRA and pharmacovigilance: a complex and little-evaluated tool.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"MedDRA (Medical Dictionary tor Regulatory Activities) is a standardised medical terminology, published by the International Council for Harmonisation, used in particular for coding cases of adverse effects in clinical study reports and pharmacovigilance databases, and to facilitate searches in these databases. MedDRA has a 5-level, hierarchical structure. Some levels are used to code adverse effects, and the others are designed to group together related terms for database searches. The links between these terms are hierarchical and complex. In addition to searches for terms, broad or narrow searches of MedDRA-coded databases can be performed using predefined \"standardised Med-DRA queries\", of which about a hundred are available in early 2016. A French study on 4 adverse effects recorded in France's national pharma- covigilance database showed that the effectiveness of MedDRA and stan- dardised MedDRA queries is highly variable, depending on the adverse effect examined. In some cases, less than half of the cases retrieved were relevant. A study on the adverse effects most frequently reported in clinical trials of 10 randomly selected drugs showed that a given adverse effect could be described using between 4 and several hundred different codes. One risk of fragmenting the reporting of adverse effects across multiple terms is that their true frequency will be underestimated. The development of a harmonised international terminology is a worth-while endeavour. But the complexity of MedDRA and its poorly evaluated performance make it susceptible to manipulation, errors of interpretation and bias. This applies in particular to the adverse effect statistics in the clinical study reports of clinical trials. The evaluation of the effectiveness of MedDRA as a tool for identifying and quantifying the adverse effects of new drugs must continue. For healthcare professionals, the limitations of MedDRA are one more reason to recognise that the known adverse effects of drugs, and their quantification, tend to be underestimated.","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":"25 175","pages":"247-250"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36909556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

bevacizumab (Avastin°) in persistent, recurrent or metastatic cervical cancer: Prolongs survival by a few months, but highly toxic. 贝伐单抗(阿瓦斯汀°)用于持续性、复发性或转移性宫颈癌:延长生存数月，但剧毒。

Prescrire International Pub Date : 2016-10-01

引用次数: 0

intravenous cangrelor (Kengrexal°) and coronary angioplasty: No advantage over first-line clopidogrel. 静脉注射康格瑞洛和冠状动脉成形术:与一线氯吡格雷相比没有优势。

Prescrire International Pub Date : 2016-10-01

引用次数: 0

Exercise useful for elderly women. 锻炼对老年妇女有益。

Prescrire International Pub Date : 2016-10-01

引用次数: 0

Idelalisib: deaths from infections. Toxicity and doubtful efficacy. Idelalisib:感染致死。毒性和可疑的功效。

Prescrire International Pub Date : 2016-10-01